Corteva (NYSE:CTVA) Rating Lowered to “Hold” at Zacks Research

Corteva (NYSE:CTVA) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

Other equities analysts have also recently issued reports about the company. Mizuho raised their price objective on Corteva from $96.00 to $97.00 and gave the company an “outperform” rating in a report on Tuesday, July 14th. UBS Group increased their price target on shares of Corteva from $86.00 to $89.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $101.00 price target on shares of Corteva in a research note on Monday, August 3rd. Jefferies Financial Group boosted their price objective on shares of Corteva from $95.00 to $97.00 in a report on Thursday, May 7th. Finally, Morgan Stanley upped their price objective on shares of Corteva from $84.00 to $95.00 and gave the company an “overweight” rating in a research note on Thursday, May 28th. Fourteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, Corteva presently has a consensus rating of “Moderate Buy” and an average price target of $91.70.

Corteva Stock Down 0.9%

Shares of NYSE:CTVA opened at $75.57 on Tuesday. The firm has a market capitalization of $50.42 billion, a PE ratio of 50.05, a price-to-earnings-growth ratio of 2.34 and a beta of 0.57. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.10 and a current ratio of 1.52. Corteva has a 52-week low of $60.53 and a 52-week high of $90.97. The firm has a fifty day moving average of $81.83 and a 200 day moving average of $80.01.

Corteva (NYSE:CTVA) last released its quarterly earnings results on Thursday, July 30th. The company reported $2.30 earnings per share for the quarter, beating analysts’ consensus estimates of $2.24 by $0.06. Corteva had a return on equity of 10.18% and a net margin of 5.66%.The business had revenue of $6.38 billion for the quarter, compared to the consensus estimate of $6.60 billion. During the same quarter last year, the business posted $2.20 earnings per share. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.600-3.800 EPS. As a group, research analysts anticipate that Corteva will post 3.72 EPS for the current fiscal year.

Institutional Trading of Corteva

Several hedge funds and other institutional investors have recently bought and sold shares of CTVA. Compass Financial Management LLC bought a new position in shares of Corteva in the second quarter worth approximately $25,000. JPL Wealth Management LLC bought a new stake in Corteva during the 3rd quarter valued at $25,000. Garton & Associates Financial Advisors LLC bought a new stake in Corteva during the 4th quarter valued at $27,000. Bank of Jackson Hole Trust purchased a new stake in Corteva during the 4th quarter valued at $28,000. Finally, Cornerstone Financial Management LLC purchased a new stake in Corteva during the 4th quarter valued at $29,000. Institutional investors own 81.54% of the company’s stock.

About Corteva

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.